Sage Therapeutics R&D Chief Maintains Equity Stake Amid Key Development Phase

Rhea-AI Filing Summary

Sage Therapeutics (SAGE) reported insider trading activity through a Form 4 filing for Chief Scientific Officer and Interim Head of R&D Michael C. Quirk. On June 24, 2025, Quirk disposed of 113 shares at a price of $9.22 per share through a tax withholding transaction (Code F).

The transaction was related to the vesting of 338 time-based restricted stock units (RSUs) that were originally granted on October 28, 2021, under the company's 2014 Stock Option and Incentive Plan. The RSUs vest on a schedule of 25% initial vesting on September 24, 2022, followed by twelve equal quarterly installments.

Following the reported transaction, Quirk directly owns 30,461 shares of Sage Therapeutics common stock. The Form 4 was filed on behalf of Quirk by attorney-in-fact Brandon Marsh on June 26, 2025.

Insider Trade Summary

Net Seller: 113 shares

Net Sell 1 txn

Insider Quirk Michael C.

Role See Remarks

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	113	$9.22	$1K

Holdings After Transaction: Common Stock — 30,461 shares (Direct)

Footnotes (1)

1. F1. On June 24, 2025, the reporting person vested 338 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.

FAQ

How many shares did SAGE's Chief Scientific Officer Michael Quirk dispose of on June 24, 2025?

On June 24, 2025, Michael Quirk disposed of 113 shares of SAGE common stock at a price of $9.22 per share. These shares were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs).

How many SAGE shares does Michael Quirk own after the June 24, 2025 transaction?

Following the reported transaction on June 24, 2025, Michael Quirk directly owns 30,461 shares of SAGE Therapeutics common stock.

What is the vesting schedule for Michael Quirk's RSUs at SAGE Therapeutics?

The RSUs were granted on October 28, 2021, under the Sage Therapeutics 2014 Stock Option and Incentive Plan. The vesting schedule includes an initial 25% vest on September 24, 2022, followed by twelve equal quarterly installments thereafter.

What is Michael Quirk's current position at SAGE Therapeutics as of June 2025?

Michael Quirk serves as Chief Scientific Officer and Interim Head of R&D at Sage Therapeutics, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/26/2025 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quirk Michael C.

(Last) (First) (Middle)

C/O SAGE THERAPEUTICS, INC.

55 CAMBRIDGE PARKWAY

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sage Therapeutics, Inc. [ SAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/24/2025		F		113(1)	D	$9.22	30,461	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On June 24, 2025, the reporting person vested 338 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.

Remarks:

Chief Scientific Officer and Interim Head of R&D

	Brandon Marsh, attorney in fact for Michael C. Quirk	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.